Navigation Links
AXA Equitable Meets the Needs of Two People under One Life Insurance Policy
Date:3/3/2008

NEW YORK, March 3 /PRNewswire-FirstCall/ -- Today AXA Equitable unveiled its new Athena Survivorship Universal Life(SM) III (Athena SUL III) insurance product, designed to deliver cost-effective death benefit protection to couples and business partners for their estate, business and charitable planning needs. By providing a death benefit upon the death of the surviving insured, Athena SUL III can be used to pay sizeable estate taxes and other expenses. Athena SUL III introduces a new Preferred Plus underwriting class and, for an additional charge, offers policyholders an optional Lapse Protection Rider (LPR) that guarantees the policy premium against fluctuations in interest crediting rates or increases in policy charges, as long as certain requirements are met. "Adding Athena SUL III to AXA Equitable's product portfolio," said Claude Methot, Senior Vice President and Chief Product Officer, who made today's announcement, "ensures that we're providing a wide range of solutions to meet every life insurance need, from a business' key person protection to a couple's wealth transfer."

Two People. Many Needs.

Any two people may have different reasons for needing joint coverage under a survivorship universal life insurance policy. Athena SUL III is designed to meet these many needs, including:

-- Wealthy married couples who desire competitively-priced guaranteed

death benefit coverage for estate liquidity or other wealth transfer

purposes.

-- Married couples who desire to use life insurance to make leveraged

charitable bequests.

-- Businesses that have at least two owners or key employees and want to

take advantage of a cost-effective survivorship universal life policy

versus paying premiums on two single life policies and can afford to

wait on death benefit proceeds until the death of the surviving

insured.

-- Dual wage-earners who have a special-needs famil
'/>"/>

SOURCE AXA Equitable
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. AXA Equitable Helps Americans Prepare for a Long Retirement
2. AUDIO from Medialink and AXA Equitable: Timing Retirement Thinking
3. Can world prize competitions foster more equitable drug research and development?
4. AXA Equitable Makes it Easier to Stop Ignoring Life Insurance
5. San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism
6. David Kahal Joins AXA Equitable as National Sales Manager
7. AXA Equitable Life Insurance Co. Hires William McDermott to Lead Corporate Retirement Planning Business
8. Midwest Meets West Coast, The Chicago School of Professional Psychology to Open New Campus in Downtown Los Angeles
9. Chronic Pain Meets Its Match
10. East Meets West at Cabo San Lucas New Saltwater Spa, Opening February
11. MEDRAD Mobile MR Injector Meets Challenges of MR Trailers
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10BioCryst Provides Update Regarding Peramivir for Influenza 5116 1BioCryst Provides Update Regarding Peramivir for Influenza 5116 2BioCryst Provides Update Regarding Peramivir for Influenza 5116 3BioCryst Provides Update Regarding Peramivir for Influenza 5116 4BioCryst Provides Update Regarding Peramivir for Influenza 5116 5Study explores how life experiences contribute to the biological changes of Alzheimers 10197 1Study explores how life experiences contribute to the biological changes of Alzheimers 10197 2Study explores how life experiences contribute to the biological changes of Alzheimers 10197 3Doctor Visits Are Getting Short Shrift in Tight Economy 58589 1Doctor Visits Are Getting Short Shrift in Tight Economy 58589 2